Among the other half of pediatric Ph-like ALL subgroups without CRLF2 rearrangement, 15–20% harbored ABL-class gene fusions including ABL1, ABL2, PDGFRA, PDGFRB, LYN, and CSF1R lesions, which are potential targets for an ABL-class first-generation tyrosine kinase inhibitor—imatinib—or a second-generation multikinase ABL1/SRC inhibitor—dasatinib [27,44,45,46]. Here, ABL2 is linked to acute lymphoblastic leukemia.